Top Global CROs by Revenue

The CRO industry has experienced remarkable growth over the past decade, driven by increasing pharmaceutical R&D spending, the complexity of modern drug development, and the increasing reliance of outsourced clinical trials. As biopharma companies seek to accelerate time-to-market while managing costs, they increasingly rely on CROs to handle everything from study design and patient recruitment to regulatory submissions and data management. This shift has created a highly competitive landscape where scale, geographic reach, and therapeutic expertise determine market leadership.

Revenue serves as a key indicator of a CRO's market position, reflecting not only their ability to win and execute large-scale clinical programs but also their operational capacity and client trust. The largest global CROs have built their dominance through strategic acquisitions, international expansion, and comprehensive service offerings that span the entire drug development lifecycle. From early-phase studies to post-market surveillance, these industry leaders have positioned themselves as indispensable partners to pharmaceutical companies worldwide, generating billions in annual revenue while advancing medical innovation across diverse therapeutic areas.

---

COG: CRO Summit brings together International leaders from Contract Research Organizations and functional service providers in the Raleigh-Durham Research Triangle to advance operational excellence and innovation in clinical trial delivery.

This premier two-day gathering delivers actionable insights on emerging technologies, strategic collaboration, and the evolving landscape of the global CRO industry.

Find Our More Here: https://www.thepbcgroup.com/crosummit

---

IQVIA

IQVIA Holdings Inc. is the world's largest clinical research organization, headquartered in Durham, North Carolina. The company reported impressive full-year 2024 revenue of $15.4 billion, positioning it as the undisputed leader in the global CRO market. IQVIA employs approximately 88,000 people across more than 100 countries, making it one of the largest healthcare services organizations globally.

The company operates through three main divisions: Research & Development Solutions (55% of revenue), which handles clinical trials from Phase I through IV; Technology & Analytics Solutions (40% of revenue), offering cloud-based healthcare analytics and data services; and Contract Sales & Medical Solutions (5% of revenue), providing commercial outsourcing services. IQVIA's key markets span all major pharmaceutical regions, with strong presence in North America, Europe, and Asia-Pacific. The company leverages its global footprint to support clinical trials and data analytics across diverse therapeutic areas, with particular strength in oncology, immunology, and emerging markets throughout Latin America and Asia where pharmaceutical growth is accelerating rapidly.

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is a major American life sciences company that has emerged as a significant player in the CRO market through strategic acquisitions, particularly its $17.4 billion acquisition of PPD, Inc. in 2021. The company reported full-year 2024 revenue of $42.88 billion, maintaining flat growth compared to the prior year. Thermo Fisher employs approximately 125,000 people globally, making it one of the largest life sciences organizations worldwide.

Headquartered in Waltham, Massachusetts, the company operates through multiple business segments, with its PPD clinical research division serving as a leading global CRO. The company's revenue is geographically distributed across the United States ($22.5 billion), Europe ($10.86 billion), Asia-Pacific ($7.96 billion), and other regions ($1.56 billion). Through PPD, Thermo Fisher provides comprehensive clinical development services across more than 20 therapeutic areas, with approximately 6,000 staff in the Asia-Pacific region alone and over 25 years of local experience. The company's key markets include North America, Europe, and Asia-Pacific, where it offers integrated drug development solutions from early-phase studies through commercialization, supported by its extensive global network of clinical research facilities and regulatory expertise.

ICON

ICON PLC is an Irish-headquartered global clinical research organization that has established itself as a major player in the CRO market. The company reported full-year 2024 revenue of $8.28 billion, representing a 2.0% increase from the previous year. ICON employs approximately 41,900 people globally, making it one of the largest CROs worldwide.

Founded in Dublin, Ireland in 1990, ICON operates through a comprehensive global network spanning 106 locations across 55 countries. The company's geographic structure is organized into four main segments: Ireland, the rest of Europe, the United States, and other international markets. ICON has maintained a presence in Asia-Pacific since 1995 and in Latin and Central America since 1998, demonstrating strong regional expertise and local knowledge. Beyond its physical offices, ICON can provide service delivery in a total of 93 countries through locally based remote staff and partnerships with third-party providers. The company's key markets include North America, Europe, and Asia-Pacific, where it offers comprehensive clinical development services from Phase I through IV trials, with particular strength in complex therapeutic areas and specialized patient populations across its extensive global footprint.

Syneos Health

Syneos Health Inc. is a leading American biopharmaceutical solutions organization that was taken private in August 2023 by a consortium of private equity firms including Elliott Investment Management, Patient Square Capital, and Veritas Capital. The company's most recent public financial data shows annual revenue of approximately $5.4 billion, making it one of the larger players in the CRO market. As of 2022, the company's clinical services business contributed 75% of its revenue while commercial services accounted for the remaining 25%. Syneos Health employs approximately 24,000-29,000 professionals globally.

Based in Morrisville, North Carolina, Syneos Health was formed from the merger of InVentiv Health and INC Research, creating a unique integrated biopharmaceutical solutions organization combining both CRO and CCO (Contract Commercial Organization) capabilities. The company has the ability to support customers in more than 110 countries, with a particularly strong presence in key pharmaceutical markets. Syneos Health Consulting has established a global presence with consulting professionals across North America, Europe, and Asia-Pacific, operating as a unified worldwide practice. Key markets include North America (with headquarters in North Carolina and multiple offices across major U.S. cities), Europe (with 250+ European healthcare communications experts serving the 20 most important markets in Europe), and Asia-Pacific, where the company has expanded through acquisitions like Kinapse, providing significant operations in India, China, Singapore, and Japan to support both regional clients and global project delivery.

Parexel

Parexel International Corporation is one of the world's largest contract research organizations, founded in 1982 and headquartered in Durham, North Carolina. The company was taken private in September 2017 by Pamplona Capital Management for $5 billion, and by that time had more than $2 billion in annual revenues. Current estimates indicate Parexel's annual revenue is $3.8 billion. With a global workforce of approximately 21,000 employees in 2025, Parexel provides comprehensive clinical research services across Phase I-IV trials.

Parexel operates through a robust global network with offices spanning six continents. The company has established a particularly strong presence in key growth markets, with 5,100+ staff across 10+ offices in North America, including headquarters in Durham, North Carolina, early phase clinics in Baltimore and LA, and clinical trial supplies facilities in Pennsylvania. In Asia-Pacific, the company employs 8,800+ staff across 20+ offices, with clinical trial supplies and logistics depots in China and Singapore. Parexel's key markets include North America, Europe, Asia-Pacific, and Latin America, where it leverages local expertise and regulatory knowledge. The company has been particularly active in expanding its footprint in emerging markets, including a strong presence across Asia-Pacific countries such as China, Japan, India, Australia, and Southeast Asian markets, as well as growing operations in Latin America, the Middle East, and Africa.

Medpace

Medpace Holdings, Inc. is a Cincinnati-based global clinical research organization that has established itself as a prominent mid-sized player in the CRO market. The company reported full-year 2024 revenue of $2.109 billion, representing 11.8% growth from the previous year. Medpace employs approximately 5,900 people across 44 countries as of December 2024, having grown from over 5,400 employees across 40 countries reported earlier in the year.

Founded in 1992 by Dr. August J. Troendle, a former FDA reviewer, Medpace operates as a full-service CRO specializing in Phase I-IV clinical development services with particular strength in serving small and mid-sized biotechnology, pharmaceutical, and medical device companies. The company's resources extend across North America, Europe, Latin America, and Asia Pacific with strong site and investigator relationships. Medpace provides local expertise with global resources, facilitating projects through regional offices located on six continents, including regional offices in Dallas, Denver, and Mexico City for North American support. The company's key markets span major pharmaceutical regions, with particularly strong European presence through partnerships with organizations like UK NIHR CRN, UK Experimental Cancer Medicine Centre, and key investigator sites across the EU, Central and Eastern Europe, Israel, and South Africa, while also maintaining significant operations in Asia-Pacific and Latin American markets to serve diverse patient populations globally.